Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence
**Background:** Varenicline is a smoking cessation medication. **Objectives:** We analyzed patients’ out-of-pocket costs and utilization of and persistence with varenicline. **Methods:** De-identified claims data in the MarketScan® Commercial Claims and Encounters Database were analyzed retrospect...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2014-08-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9888 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860356497276928 |
|---|---|
| author | Aaron Galaznik Katherine Cappell Leslie Montejano Geoffrey Makinson Kelly H. Zou Gregory Lenhart |
| author_facet | Aaron Galaznik Katherine Cappell Leslie Montejano Geoffrey Makinson Kelly H. Zou Gregory Lenhart |
| author_sort | Aaron Galaznik |
| collection | DOAJ |
| description | **Background:** Varenicline is a smoking cessation medication.
**Objectives:** We analyzed patients’ out-of-pocket costs and utilization of and persistence with varenicline.
**Methods:** De-identified claims data in the MarketScan® Commercial Claims and Encounters Database were analyzed retrospectively. Participants were all patients at least 18 years of age continuously enrolled in plans during 2009. Plans were categorized according to restriction (no coverage; prior authorization; smoking cessation program requirement; no restrictions) and out-of-pocket cost for a 30-day supply (low: <US$12; medium: US$12–24.99; high: ≥US$25). The main outcome measures were utilization (defined as presence of a drug claim) and persistence (according to days’ supply and number of days to discontinuation). Generalized linear models and time-to-event analyses were conducted.
**Results:** There were 142,251, 458,966 and 222,241 individuals in the low, medium and high out-of-pocket cohorts, respectively. The reference group for all comparisons was the cohort with no access restrictions and low out-of-pocket costs. Higher out-of-pocket cost was associated with a lower likelihood of varenicline initiation for both the prior authorization (odds ratio [OR]=0.10, p<0.001) and smoking cessation program requirement (OR=0.19, p<0.001) groups, versus the no restriction cohort. Within the no access restriction cohort, subjects in the high out-of-pocket group were half as likely to complete a varenicline course versus the low out-of-pocket group (OR=0.47; p<0.002). Conversely, for the smoking cessation program requirement cohort, compared to the low out-of-pocket no restriction cohort, subjects who were in the high out-of-pocket group were more likely to complete a varenicline course (OR=0.70; p=0.13) than those in the low out-of-pocket group (OR=0.38; p=0.04).
**Conclusions:** Higher varenicline out-of-pocket costs were generally associated with lower utilization of and persistence with treatment. These findings have implications for coverage policies in health plans and employers seeking to encourage smoking cessation. |
| format | Article |
| id | doaj-art-8a305048b2dd4157bc3429b89a329ae2 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2014-08-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-8a305048b2dd4157bc3429b89a329ae22025-02-10T16:13:01ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362014-08-0121Impact of Out-of-pocket Costs on Varenicline Utilization and PersistenceAaron GalaznikKatherine CappellLeslie MontejanoGeoffrey MakinsonKelly H. ZouGregory Lenhart**Background:** Varenicline is a smoking cessation medication. **Objectives:** We analyzed patients’ out-of-pocket costs and utilization of and persistence with varenicline. **Methods:** De-identified claims data in the MarketScan® Commercial Claims and Encounters Database were analyzed retrospectively. Participants were all patients at least 18 years of age continuously enrolled in plans during 2009. Plans were categorized according to restriction (no coverage; prior authorization; smoking cessation program requirement; no restrictions) and out-of-pocket cost for a 30-day supply (low: <US$12; medium: US$12–24.99; high: ≥US$25). The main outcome measures were utilization (defined as presence of a drug claim) and persistence (according to days’ supply and number of days to discontinuation). Generalized linear models and time-to-event analyses were conducted. **Results:** There were 142,251, 458,966 and 222,241 individuals in the low, medium and high out-of-pocket cohorts, respectively. The reference group for all comparisons was the cohort with no access restrictions and low out-of-pocket costs. Higher out-of-pocket cost was associated with a lower likelihood of varenicline initiation for both the prior authorization (odds ratio [OR]=0.10, p<0.001) and smoking cessation program requirement (OR=0.19, p<0.001) groups, versus the no restriction cohort. Within the no access restriction cohort, subjects in the high out-of-pocket group were half as likely to complete a varenicline course versus the low out-of-pocket group (OR=0.47; p<0.002). Conversely, for the smoking cessation program requirement cohort, compared to the low out-of-pocket no restriction cohort, subjects who were in the high out-of-pocket group were more likely to complete a varenicline course (OR=0.70; p=0.13) than those in the low out-of-pocket group (OR=0.38; p=0.04). **Conclusions:** Higher varenicline out-of-pocket costs were generally associated with lower utilization of and persistence with treatment. These findings have implications for coverage policies in health plans and employers seeking to encourage smoking cessation.https://doi.org/10.36469/9888 |
| spellingShingle | Aaron Galaznik Katherine Cappell Leslie Montejano Geoffrey Makinson Kelly H. Zou Gregory Lenhart Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence Journal of Health Economics and Outcomes Research |
| title | Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence |
| title_full | Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence |
| title_fullStr | Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence |
| title_full_unstemmed | Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence |
| title_short | Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence |
| title_sort | impact of out of pocket costs on varenicline utilization and persistence |
| url | https://doi.org/10.36469/9888 |
| work_keys_str_mv | AT aarongalaznik impactofoutofpocketcostsonvareniclineutilizationandpersistence AT katherinecappell impactofoutofpocketcostsonvareniclineutilizationandpersistence AT lesliemontejano impactofoutofpocketcostsonvareniclineutilizationandpersistence AT geoffreymakinson impactofoutofpocketcostsonvareniclineutilizationandpersistence AT kellyhzou impactofoutofpocketcostsonvareniclineutilizationandpersistence AT gregorylenhart impactofoutofpocketcostsonvareniclineutilizationandpersistence |